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Epidermal growth factor receptor gene expression in response to the tumor promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) 
was analyzed in the AS49 human lung adenocarcinoma cell line using DNA transfection. After 8 h of treatment a definite repression (45%) of 
EGF receptor gene transcription could be seen. Repression was maintained for up to 24 h. Little or no induction of transcription could be seen 
prior to the onset of repression for potential enhancer egions both upstream and downstream of the translation start site. The &element(s) respon- 
sible for repression were localized between residues -384 and -151 of the EGF receptor gene promoter egion using a deletion plasmid series. 
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1. INTRODUCTION 
Epidermal growth factor (EGF) interacts with the 
EGF receptor to stimulate growth and proliferation of 
a variety of cells in vitro and in vivo [1,2]. The EGF 
receptor gene is homologous to the product of the v-erb 
B oncogene [3] and over-expression of normal EGF 
receptors on the cell surface via expression vector 
transfection has been shown to transform Swiss 3T3 
cells in an EGF dependent manner [4,5]. Recently, we 
showed that squamous cell carcinomas of esophagus 
and lung have significantly higher levels of EGF recep- 
tors in primary tumor tissue than adjacent tissue or 
other carcinomas [6,7]. Furthermore, we suggested that 
the increase in receptor number plays an important role 
in the growth of these tumors as well as their malignan- 
cies [8]. These data indicate that strict regulation of 
EGF receptor gene expression is critical for normal cell 
growth. In an effort to ascertain mechanisms of this 
regulation we have looked at the transcriptional re- 
sponse of the EGF receptor gene to the tumor promoter 
TPA in the A549 human lung adenocarcinoma cell line 
using DNA transfection analysis. We find that the EGF 
receptor gene is repressed after exposure to TPA with 
little or no evidence of induction. The &elements 
responsible for this repression were localized. These 
results are discussed in light of other recent findings. 
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2. MATERIALS AND METHODS 
2.1. Cell maintenance ond TPA treatment 
A549 cells were maintained in a 1: 1 mixture of Dulbecco’s 
modified Eagle’s medium and RPM1 1640 supplemented with 10% 
fetal bovine serum, penicillin and streptomycin. Cells were treated 
for the indicated times with TPA (Sigma), dissolved in DMSO at a 
final concentration of 20 ng per ml of media. Control cells were 
treated with DMSO only for equal amounts of time. 
2.2. Plasmid construction 
The insert of pERCAT- [9] containing 1.1 kb of EGF receptor 
gene regulatory region was isolated after Hind111 restriction digest. It 
was subsequently digested with Toql, DdeI, AvoII and EgfI separate- 
ly and relevant fragments were isolated. Fragments were blunt-ended 
with Klenow fragment or T4 DNA polymerase followed by Hind111 
linker ligation using T4 DNA ligase. Resulting fragments were in- 
troduced into the pSVOCAT vector Hind111 site [lo]. Recombinants 
were screened for correct orientation by restriction enzyme mapping. 
Plasmids containing additional regulatory domains were constructed 
by similar methods. pERCAT-Ex2.2 was created by isolating an 
EcoRl-Sac1 2.2 kb fragment from PEPS which contains a 5.2 kb 
genomic insert as described [lo]. The insert was XhoI linkered and 
cloned into an XhoI linkered Hind111 site in pSVOCAT. pERCAT- 
Int2.2 contains a 2.2 kb PvuII-FvuII insert also derived from PEPS. 
The 2.2 kb insert was BomHI linkered and cloned into the BomHI site 
of pERCAT-I. 
2.3. DNA tronsfection ond CAT assoy 
Deletion plasmids were transiently transfected into A549 cells as 
described previously [ll]. Briefly, 6 x 10’ cells were seeded in 10 cm 
tissue culture dishes 20 h prior to transfection. 7 pg of CAT plasmid 
and 3 pg of a plasmid containing the ,&galactosidase gene @CHl 10) 
[12] as an internal control were transfected per plate. Five h post 
transfection the cells were glycerol shocked. Cells were then incubated 
in normal growth media for 48 h after which cells were lysed with 
three freeze-thaw cycles. CAT [ll] and b-gal [I21 assays were per- 
formed as previously described. 
3. RESULTS 
To clarify the transcriptional effects of TPA on EGF 
receptor gene expression, DNA transfection analysis 
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Fig. 1. Structure of EGFR-CAT plasmids. Plasmids were created as described in Materials and Methods. Thin solid lines represent regulatory DNA 
contained within a given plasmid. Dashed lines represent pSVOCAT sequences. 
was carried out using plasmids containing regulatory 
regions of the EGF receptor gene (Fig. 1). Time course 
analysis with pERCAT- revealed repression of EGF 
receptor gene expression. This repression could not be 
seen until approximately 5 h after TPA treatment; 
reaching a maximum by 8 hours and staying constant 
up to 24 h (Fig. 2). At no point could significant induc- 
tion of transcription be seen. 
This lack of induction in response to TPA was sur- 
prising because steady-state EGF receptor mRNA ac- 
cumulation in A549 cells seems highly sensitive to TPA. 
Previous results showed an approximate 10 fold in- 
crease in EGF receptor mRNA in Northern blot 
analysis after 4-6 h of TPA treatment. Additional ex- 
periments suggested a transcriptional mechanism 
responsible for this induction (S. Gamou, unpublished 
observations). To test the theory that &elements 
responsive to TPA residue outside of the region tested, 
we examined two additional -potential regulatory 
regions. Plasmid pERCAT-Ex2.2 contains an addi- 
tional 1.1 kb of DNA directly upstream of that contain- 
ed within pERCAT-I. pERCAT-Int2.2 contains 2.2 kb 
of DNA from the first intron (Fig. 1). Both regions 
have been suggested to contain enhancer elements [121. 
As shown in figure 3a, no induction of CAT activity 
could be seen with either of the plasmid constructs after 
4 h of TPA treatment which coincides with the point of 
maximum mRNA accumulation. These results suggest 
either that TPA induced expression of EGF receptor 
mRNA occurs by a mechanism not involving an in- 
crease in transcription or that the c&element conferring 
transcriptional responsiveness to TPA is not contained 
within any of the plasmids thus far examined. Ex- 
periments are currently underway to address this ques- 
tion. 
To localize the &elements required for repression, 
deletion plasmids were constructed from pERCAT- as 
shown in Fig. 1. pERCAT- exhibited 43% repression 
after 16 h TPA exposure (Fig. 3b). This value was quite 
constant for a number of deletion plasmids as shown in 
“.‘~ 
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Fig. 2. CAT analysis: time course. Induction or repression was deter- 
mined by comparison with DMSO control for each time point includ- 
ed. The results are typical of numerous trials. 
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Fig. 3. (a) CAT analysis: pERCAT-Ex2.2 and pERCAT-Int2.2. 
Assays were done in triplicate with standard error shown. %CAT ac- 
tivity was determined comparing cells transfected and treated with 
TPA for 4 h vs cells transfected and treated with DMSO. 1, 2: 
pERCAT-Int2.2. 3, 4: pERCAT-Ex2.2. ‘T’ corresponds to TPA 
treated cells and ‘D’ corresponds to DMSO treated cells. (b) CAT 
analysis: deletion plasmids. Assays were done in triplicate with stan- 
dard error shown except for pERCAT-Tag1 and pERCAT-DdeI 
which are the results of a single experiment. Transfected wells were 
treated with TPA for 16 h and compared to control cells treated with 
DMSO for an equal amount of time. 1,2: pERCAT-I; 3,4: pERCAT- 
TaqI; 5, 6: pERCAT-DdeI; 7, 8: pERCAT-AvaII; 9, 10: pERCAT- 
BglI. 
Fig. 3b including pERCAT-AvaII which contains only 
384 bp of upstream DNA and exhibited 47% repres- 
sion. The deletion plasmid containing 5 ‘DNA from 
- 16 to - 151, however, showed only 14% repression 
after 16 h TPA treatment. These results indicate that 
the major &element(s) required for TPA induced 
repression reside with a 230 bp sequence between - 384 
and -151. 
4. DISCUSSION 
A number of factors including TPA, EGF and reti- 
noic acid can cause an increase in EGF receptor mRNA 
accumulation in a variety of cell lines [ 13-171. The 
mechanism responsible for this accumulation is 
unclear. Clark et al. suggest that treatment of A43 1 cells 
with EGF leads to enhanced mRNA stability [14]. 
Others, however, suggest hat the increase in mRNA 
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seen after EGF treatment of MDA468 cells could not be 
due to mRNA stability alone [ 171. In our study, A549 
cells transiently transfected with up to 3.3 kb of EGF 
receptor gene regulatory region showed no significant 
induction of transcription after TPA treatment. How- 
ever, repression of transcription could clearly be seen 
with a maximum repression at 8 h. This time closely ap- 
proximates the point of maximum EGF receptor 
mRNA accumulation in MDA468 human breast cancer 
cells after TPA treatment [ 171. 
Deletion analysis localized the major &element con- 
ferring repression between residues - 384 and - 151. 
This region has been characterized for a number of 
regulatory proteins including GCF, a DNA binding 
protein recently shown to repress EGF receptor gene 
transcription [18]. We speculate the GCF may be 
responsible for the repression of EGF receptor gene 
transcription after TPA treatment. Two binding sites 
for GCF occur within the region - 384 to - 15 1. Addi- 
tionally, one weak binding site occurs between - 90 and 
- 151 which may be responsible for the low level of 
repression seen with the - 16 to - 151 plasmid. 
These results suggest a complex regulatory response 
of the EGF receptor gene to TPA involving both 
positive regulation perhaps by mRNA stabilization and 
negative regulation at the level of transcription via the 
putative activity of GCF. Such complexity may be 
necessary to modulate the response to various mitogens 
including TPA and EGF. 
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